NCT01172717View on ClinicalTrials.gov

Study of Panitumumab in the Treatment of Carcinoid Syndrome

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Carcinoid Syndrome
Interventions
DRUG

Panitumumab

Panitumumab will be given by intravenous infusion at a dose of 9 mg/kg on day 1 of study and then every 3 weeks until progression of disease

Trial Locations (2)

02118

Boston Medical Center, Boston

01805

Lahey Clinic, Burlington

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Boston Medical Center

OTHER